5AM Venture Management LLC Sells 200,000 Shares of Entrada Therapeutics, Inc. $TRDA

5AM Venture Management LLC decreased its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 4.7% during the 4th quarter, HoldingsChannel reports. The fund owned 4,056,379 shares of the company’s stock after selling 200,000 shares during the period. Entrada Therapeutics comprises approximately 13.1% of 5AM Venture Management LLC’s portfolio, making the stock its largest holding. 5AM Venture Management LLC owned 0.11% of Entrada Therapeutics worth $41,700,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. State of Wyoming lifted its holdings in Entrada Therapeutics by 130.9% during the 2nd quarter. State of Wyoming now owns 7,575 shares of the company’s stock worth $51,000 after buying an additional 4,295 shares during the period. Russell Investments Group Ltd. lifted its holdings in Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after buying an additional 3,707 shares during the period. AXQ Capital LP acquired a new position in Entrada Therapeutics during the 3rd quarter worth about $67,000. Occudo Quantitative Strategies LP acquired a new position in Entrada Therapeutics during the 2nd quarter worth about $68,000. Finally, Jain Global LLC acquired a new position in Entrada Therapeutics during the 3rd quarter worth about $69,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

Insider Buying and Selling

In other Entrada Therapeutics news, insider Natarajan Sethuraman sold 25,907 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $15.39, for a total transaction of $398,708.73. Following the completion of the sale, the insider directly owned 216,317 shares of the company’s stock, valued at approximately $3,329,118.63. The trade was a 10.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Nathan J. Dowden sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $15.33, for a total value of $229,950.00. Following the sale, the chief operating officer directly owned 198,588 shares of the company’s stock, valued at $3,044,354.04. This represents a 7.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 43,407 shares of company stock valued at $661,034. Company insiders own 9.49% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. Wall Street Zen downgraded Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Guggenheim lowered their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. HC Wainwright lowered Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Oppenheimer lifted their price objective on Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a research report on Monday, April 6th. Finally, Roth Mkm set a $10.00 price objective on Entrada Therapeutics in a research report on Friday, May 8th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $17.50.

Entrada Therapeutics Price Performance

Shares of Entrada Therapeutics stock opened at $6.81 on Thursday. Entrada Therapeutics, Inc. has a one year low of $4.93 and a one year high of $16.45. The firm has a market capitalization of $264.36 million, a price-to-earnings ratio of -1.71 and a beta of -0.26. The business has a 50-day simple moving average of $9.43 and a 200 day simple moving average of $10.63.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.95) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.11. The firm had revenue of $0.88 million during the quarter, compared to analyst estimates of $2.92 million. Entrada Therapeutics had a negative return on equity of 51.22% and a negative net margin of 2,895.05%. On average, sell-side analysts expect that Entrada Therapeutics, Inc. will post -4.12 EPS for the current year.

Entrada Therapeutics Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.